UOC
VINC

UBS O'Connor’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

UBS O'Connor’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,875
Closed -$550K – 1019
2022
Q1 		$550K Buy
+6,875
New +$849K 0.01% 743

Other funds holding VINC

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

UBS O'Connor's VINC Position: Q2 2022 in Review

UBS O'Connor sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2022, closing a stake of 6,875 shares — an estimated $550K sold.

UBS O'Connor first reported a position in VINC in Q1 2022 and held it in 1 quarter. The position peaked at $550K in Q1 2022. 51 funds tracked by Wall St. Rank hold VINC as of Q2 2022.

  • UBS O'Connor reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • UBS O'Connor sold 6,875 Vincerx Pharma, Inc. Common Stock shares in Q2 2022, an estimated $550K.
  • UBS O'Connor first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • UBS O'Connor's Vincerx Pharma, Inc. Common Stock position peaked at $550K in Q1 2022.
  • 51 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2022.

Based on UBS O'Connor's 13F filing for Q2 2022, filed 12 Aug 2022.